# Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

> **NCT04632459** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 35 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** pembrolizumab plus ramucirumab

## Key facts

- **NCT ID:** NCT04632459
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-16
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632459, "Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04632459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*